Lexaria Bioscience receives Nasdaq delisting notice but expects compliance via reverse split

Lexaria Bioscience Corp.

Received Nasdaq delisting notice Aug 4, 2026 for failing to regain $1 minimum bid price within 180-day period.
Completed reverse stock split Aug 3, 2026 (announced Jul 30); shares now trading above $1 under CUSIP 52886N604.
Filed hearing request and paid fee to stay delisting; expects to regain compliance before hearing date.
Company expects shares to continue trading on Nasdaq without interruption.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.